Characteristics of the pulmonary microbiota in patients with mild and severe pulmonary infection.
pulmonary infection
biomarker
network
pulmonary microbiota
severity
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
12
09
2023
medline:
31
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Lung infection is a global health problem associated with high morbidity and mortality and increasing rates of hospitalization. The correlation between pulmonary microecology and infection severity remains unclear. Therefore, the purpose of this study was to investigate the differences in lung microecology and potential biomarkers in patients with mild and severe pulmonary infection. Patients with pulmonary infection or suspected infection were divided into the mild group (140 cases) and the severe group (80 cases) according to pneomonia severity index (PSI) scores. Here, we used metagenomic next-generation sequencing (mNGS) to detect DNA mainly from bronchoalveolar lavage fluid (BALF) collected from patients to analyze changes in the lung microbiome of patients with different disease severity. We used the mNGS to analyze the pulmonary microecological composition in patients with pulmonary infection. The results of alpha diversity and beta diversity analysis showed that the microbial composition between mild and severe groups was similar on the whole. The dominant bacteria were Here, we describe the composition and diversity of the pulmonary microbiome in patients with pulmonary infection. A significant increase in viral replication was found in the severe group, as well as a significant difference in microbial interactions between patients with mild and severe lung infections, particularly the association between the common pathogenic bacteria and
Sections du résumé
Background
Lung infection is a global health problem associated with high morbidity and mortality and increasing rates of hospitalization. The correlation between pulmonary microecology and infection severity remains unclear. Therefore, the purpose of this study was to investigate the differences in lung microecology and potential biomarkers in patients with mild and severe pulmonary infection.
Method
Patients with pulmonary infection or suspected infection were divided into the mild group (140 cases) and the severe group (80 cases) according to pneomonia severity index (PSI) scores. Here, we used metagenomic next-generation sequencing (mNGS) to detect DNA mainly from bronchoalveolar lavage fluid (BALF) collected from patients to analyze changes in the lung microbiome of patients with different disease severity.
Result
We used the mNGS to analyze the pulmonary microecological composition in patients with pulmonary infection. The results of alpha diversity and beta diversity analysis showed that the microbial composition between mild and severe groups was similar on the whole. The dominant bacteria were
Conclusion
Here, we describe the composition and diversity of the pulmonary microbiome in patients with pulmonary infection. A significant increase in viral replication was found in the severe group, as well as a significant difference in microbial interactions between patients with mild and severe lung infections, particularly the association between the common pathogenic bacteria and
Identifiants
pubmed: 37900322
doi: 10.3389/fcimb.2023.1227581
pmc: PMC10602873
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1227581Informations de copyright
Copyright © 2023 Zhan, Li, Yuan, Sun, He, Zhong and Wang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Crit Care. 2020 Jan 10;24(1):12
pubmed: 31924246
Eur J Clin Microbiol Infect Dis. 2020 Feb;39(2):369-374
pubmed: 31813078
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Sci Rep. 2017 Jan 06;7:40114
pubmed: 28059171
mBio. 2011 Feb 01;2(1):e00245-10
pubmed: 21285435
J Clin Med. 2020 Feb 27;9(3):
pubmed: 32120914
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Allergy Clin Immunol. 2015 Jan;135(1):25-30
pubmed: 25567040
Chest. 2022 Jan;161(1):64-75
pubmed: 34314673
Front Cell Infect Microbiol. 2021 Mar 11;11:541092
pubmed: 33777827
N Engl J Med. 1997 Jan 23;336(4):243-50
pubmed: 8995086
Microbiome. 2022 Dec 30;10(1):245
pubmed: 36581858
Infect Dis Ther. 2018 Mar;7(1):1-16
pubmed: 29204910
Antibiotics (Basel). 2023 Jan 10;12(1):
pubmed: 36671341
Expert Rev Respir Med. 2013 Jun;7(3):245-57
pubmed: 23734647
J Clin Microbiol. 2014 Sep;52(9):3184-9
pubmed: 24951810
Nat Rev Dis Primers. 2019 Dec 5;5(1):81
pubmed: 31804499
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
J Transl Med. 2021 Dec 7;19(1):496
pubmed: 34876129
Microbiol Spectr. 2022 Feb 23;10(1):e0190121
pubmed: 35196800
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S231-S240
pubmed: 30423048
PLoS One. 2014 Oct 20;9(10):e110240
pubmed: 25329639
Adv Sci (Weinh). 2022 Nov;9(32):e2203115
pubmed: 36031410
Crit Care. 2022 Jul 6;26(1):203
pubmed: 35794610
Nat Mater. 2021 May;20(5):593-605
pubmed: 33589798
J Glob Health. 2022 Sep 17;12:05040
pubmed: 36112521
Bioengineered. 2021 Dec;12(2):10480-10490
pubmed: 34719313
Lancet. 2015 Sep 5;386(9997):995-1007
pubmed: 26049252
Crit Care. 2022 Aug 22;26(1):252
pubmed: 35996150
Respir Res. 2022 Dec 14;23(1):345
pubmed: 36517824
Lancet Microbe. 2021 Jul;2(7):e300-e310
pubmed: 35544166
Nat Rev Microbiol. 2023 Apr;21(4):222-235
pubmed: 36385637
Zhonghua Jie He He Hu Xi Za Zhi. 2018 Apr 12;41(4):244-246
pubmed: 29690680
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668
JA Clin Rep. 2017;3(1):25
pubmed: 29457069
mSystems. 2018 Mar 13;3(2):
pubmed: 29556537
Eur Respir Rev. 2019 Jul 8;28(152):
pubmed: 31285290